Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

I thought SLC showed you Leo's response. Dana-Farber only allows him to publish efficacy data in a peer-reviewed journal at the end of the trial. So you are probably not going to see them for one year.

Outsiders can only speculate at this point. Everyone knows about the spleen lesion disappearance case. Then there's the IRB's approval for 20 more patients. Why would Dana-Farber waste their time, money and resources if Kevetrin is not working? Then there's the focus on ovarian cancer. Why would Dana-Farber choose this particular tumor? Did they choose it by flipping a coin or rolling a dice?